{"status":"OK","data":{"id":2684788,"identifier":"DVN/91V95Z","persistentUrl":"https://doi.org/10.7910/DVN/91V95Z","protocol":"doi","authority":"10.7910","publisher":"Harvard Dataverse","publicationDate":"2015-06-12","storageIdentifier":"s3://dvn-cloud:10.7910/DVN/91V95Z","latestVersion":{"id":88377,"storageIdentifier":"s3://dvn-cloud:10.7910/DVN/91V95Z","versionNumber":5,"versionMinorNumber":0,"versionState":"RELEASED","productionDate":"Production Date","lastUpdateTime":"2016-10-24T00:48:38Z","releaseTime":"2016-10-24T00:48:38Z","createTime":"2016-10-24T00:47:44Z","license":"CC0","termsOfUse":"CC0 Waiver","metadataBlocks":{"citation":{"displayName":"Citation Metadata","fields":[{"typeName":"title","multiple":false,"typeClass":"primitive","value":"Anthracycline DNA Interactions"},{"typeName":"author","multiple":true,"typeClass":"compound","value":[{"authorName":{"typeName":"authorName","multiple":false,"typeClass":"primitive","value":"Miller, Jonathan"}}]},{"typeName":"datasetContact","multiple":true,"typeClass":"compound","value":[{"datasetContactName":{"typeName":"datasetContactName","multiple":false,"typeClass":"primitive","value":"Miller, Jonathan"},"datasetContactEmail":{"typeName":"datasetContactEmail","multiple":false,"typeClass":"primitive","value":"jonathan@jonathanpmiller.com"}}]},{"typeName":"dsDescription","multiple":true,"typeClass":"compound","value":[{"dsDescriptionValue":{"typeName":"dsDescriptionValue","multiple":false,"typeClass":"primitive","value":"A brief description of the clinical effectiveness and some biochemistry of anthracyclines and other small molecules in the treatment of various cancers."}}]},{"typeName":"subject","multiple":true,"typeClass":"controlledVocabulary","value":["Chemistry"]},{"typeName":"keyword","multiple":true,"typeClass":"compound","value":[{"keywordVocabulary":{"typeName":"keywordVocabulary","multiple":false,"typeClass":"primitive","value":"DNA, anthracycline, doxrubicin, intercalation, taxol, epothilone, p53, tyrosine  kinase inhibitor, p-glycop irotein, multidrug resistance, gene"}}]},{"typeName":"depositor","multiple":false,"typeClass":"primitive","value":"Miller, Jonathan"},{"typeName":"dateOfDeposit","multiple":false,"typeClass":"primitive","value":"2015-06-12"}]}},"files":[{"label":"Anthracycline DNA Interactions.docx","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2891915,"persistentId":"doi:10.7910/DVN/91V95Z/IYWLSB","pidURL":"https://doi.org/10.7910/DVN/91V95Z/IYWLSB","filename":"Anthracycline DNA Interactions.docx","contentType":"application/vnd.ms-word.document.12","filesize":283884,"storageIdentifier":"s3://dvn-cloud:15796e33fbf-af18fd8831ae","rootDataFileId":-1,"md5":"365ebe65dcc511f06b41f74ad88d425f","checksum":{"type":"MD5","value":"365ebe65dcc511f06b41f74ad88d425f"}}},{"label":"Anthracycline DNA Interactions.pdf","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2891916,"persistentId":"doi:10.7910/DVN/91V95Z/V8IDXG","pidURL":"https://doi.org/10.7910/DVN/91V95Z/V8IDXG","filename":"Anthracycline DNA Interactions.pdf","contentType":"application/pdf","filesize":300086,"storageIdentifier":"s3://dvn-cloud:15796e389e0-b48d6253834a","rootDataFileId":-1,"md5":"ee36c1dcd25fd4699935a2cbd1453580","checksum":{"type":"MD5","value":"ee36c1dcd25fd4699935a2cbd1453580"}}},{"label":"crizotinib.png","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2891917,"persistentId":"doi:10.7910/DVN/91V95Z/D1DCFL","pidURL":"https://doi.org/10.7910/DVN/91V95Z/D1DCFL","filename":"crizotinib.png","contentType":"image/png","filesize":445245,"storageIdentifier":"s3://dvn-cloud:15796e3f921-d1049f269c7f","rootDataFileId":-1,"md5":"bfa023731d1fa54640f0ff89a340ee3f","checksum":{"type":"MD5","value":"bfa023731d1fa54640f0ff89a340ee3f"}}},{"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation","label":"DOX2__MMFF94.jpg","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2905708,"persistentId":"doi:10.7910/DVN/91V95Z/TGS42D","pidURL":"https://doi.org/10.7910/DVN/91V95Z/TGS42D","filename":"DOX2__MMFF94.jpg","contentType":"image/jpeg","filesize":24256,"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation","storageIdentifier":"s3://dvn-cloud:157f42498c2-17a3e978114e","rootDataFileId":-1,"md5":"d6e1611a03de23040cf4cc96181e59af","checksum":{"type":"MD5","value":"d6e1611a03de23040cf4cc96181e59af"}}},{"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation.","label":"DOX_MMFF94.jpg","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2905706,"persistentId":"doi:10.7910/DVN/91V95Z/G1DI3E","pidURL":"https://doi.org/10.7910/DVN/91V95Z/G1DI3E","filename":"DOX_MMFF94.jpg","contentType":"image/jpeg","filesize":42344,"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation.","storageIdentifier":"s3://dvn-cloud:157f423995b-dfb791fc6d74","rootDataFileId":-1,"md5":"8fc9b986229222b2e7fdcab3b7b45d3d","checksum":{"type":"MD5","value":"8fc9b986229222b2e7fdcab3b7b45d3d"}}},{"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation by Avogadro 1.1.1.","label":"DOX_MMFF94.pdb","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2905707,"persistentId":"doi:10.7910/DVN/91V95Z/RDH4YW","pidURL":"https://doi.org/10.7910/DVN/91V95Z/RDH4YW","filename":"DOX_MMFF94.pdb","contentType":"application/octet-stream","filesize":11536,"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation by Avogadro 1.1.1.","storageIdentifier":"s3://dvn-cloud:157f4259917-f1ff8cd2244c","rootDataFileId":-1,"md5":"7347bc6ad19f8eb3ebbad0c435ba9b8f","checksum":{"type":"MD5","value":"7347bc6ad19f8eb3ebbad0c435ba9b8f"}}},{"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation.","label":"DOX_MM.jpg","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2905709,"persistentId":"doi:10.7910/DVN/91V95Z/CHEHWE","pidURL":"https://doi.org/10.7910/DVN/91V95Z/CHEHWE","filename":"DOX_MM.jpg","contentType":"image/jpeg","filesize":43956,"description":"Doxorubicin after molecular mechanics (MMFF94) geometry optimisation.","storageIdentifier":"s3://dvn-cloud:157f426892d-564203fe1ace","rootDataFileId":-1,"md5":"1660704f082b51053b940e1ea105227e","checksum":{"type":"MD5","value":"1660704f082b51053b940e1ea105227e"}}},{"label":"Notes.txt","restricted":false,"version":1,"datasetVersionId":88377,"dataFile":{"id":2891918,"persistentId":"doi:10.7910/DVN/91V95Z/83KFLE","pidURL":"https://doi.org/10.7910/DVN/91V95Z/83KFLE","filename":"Notes.txt","contentType":"text/plain","filesize":78,"storageIdentifier":"s3://dvn-cloud:15796e4133f-fd1cc6023dbd","rootDataFileId":-1,"md5":"16924048a441e4659708afc371d0701a","checksum":{"type":"MD5","value":"16924048a441e4659708afc371d0701a"}}}]}}}